COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Selective RPE Laser Treatment (SRT) for Various Macular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00403884
Recruitment Status : Unknown
Verified November 2006 by University of Regensburg.
Recruitment status was:  Active, not recruiting
First Posted : November 27, 2006
Last Update Posted : January 13, 2010
Dr. Werner Jackstaedt Foundation
Information provided by:
University of Regensburg

Brief Summary:

In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens. The macular diseases to be treated are drusen maculopathy and geographic atrophy due to age-related macular degeneration as well as diabetic macular edema and central serous chorioretinopathy.

The beneficial effect in laser treatment is thought to be associated with the restoration of a new barrier of retinal pigment epithelium cells. If this theory is true, the destruction of the photoreceptors causing visual field defects would be only an unwanted and unnecessary side effect. Thus, SRT is able to avoid these unintentional side effects and to achieve the benefit by just treating the RPE.

In this study the clinical effect of SRT for these diseases is evaluated on a long-term basis.

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration Diabetic Maculopathy Central Serous Chorioretinopathy Procedure: Selective RPE laser treatment Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Selective RPE Laser Treatment (SRT) for Various Macular Diseases
Study Start Date : October 2004
Estimated Primary Completion Date : December 2009
Estimated Study Completion Date : August 2010

Intervention Details:
  • Procedure: Selective RPE laser treatment
    interventional SRT laser treatment
    Other Name: SRT vario, Medical Laser Center, Luebeck, Germany

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: up to 2 years ]

Secondary Outcome Measures :
  1. drusen reduction [ Time Frame: up to 2 years ]
  2. area of geographic atrophy [ Time Frame: up to 2 years ]
  3. reduction of retinal edema [ Time Frame: up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • symmetric drusen maculopathy with soft drusen both eyes
  • symmetric geographic atrophy both eyes
  • diabetic macular edema single eye
  • acute or chronic central serous chorioretinopathy

Exclusion Criteria:

  • previous laser treatment
  • previous intravitreal injections
  • choroidal neovascularization
  • visual acuity > 0.1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00403884

Layout table for location information
University Eye Hospital Regensburg
Regensburg, Germany, 93042
Sponsors and Collaborators
University of Regensburg
Dr. Werner Jackstaedt Foundation
Layout table for investigator information
Principal Investigator: Carsten Framme, MD University Eye Hospital Regensburg
Layout table for additonal information
Responsible Party: PD Dr. med. Carsten Framme, FEBO, MHM, University Eye Hospital Regensburg Identifier: NCT00403884    
Other Study ID Numbers: University Eye Hospital SRT
First Posted: November 27, 2006    Key Record Dates
Last Update Posted: January 13, 2010
Last Verified: November 2006
Keywords provided by University of Regensburg:
Geographic atrophy
macular edema
retinal pigment epithelium
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Central Serous Chorioretinopathy
Retinal Degeneration
Retinal Diseases
Eye Diseases